| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.947048 |
| 003 | CaOODSP |
| 005 | 20250630150138 |
| 006 | m o d f |
| 007 | cr |n||||||||| |
| 008 | 250117e20250213onc ob f000 0 eng d |
| 020 | |a9780660752990 |q(report) |
| 020 | |a9780660753003 |q(summary) |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aHP40-379/2025E-PDF |
| 086 | 1 |aHP40-379/2025-1E-PDF |
| 245 | 00|aUpdated recommendations on measles post-exposure prophylaxis. |
| 250 | |a[February 13, 2025 edition]. |
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cFebruary 13, 2025. |
| 264 | 4|c©2025 |
| 300 | |a1 online resource (35 pages, 7 unnumbered pages) + |esummary (5 pages) |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aIssued also in French under title: Recommandations mises à jour sur la prophylaxie post-exposition à la rougeole. |
| 500 | |aOn cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). |
| 500 | |a"Pub.: 240778"--Page 2. |
| 500 | |a"Pub.: 240780"--Page 2 (summary). |
| 504 | |aIncludes bibliographical references (pages 30-35). |
| 520 | |a"The objective of this advisory committee statement is to review the criteria for expected measles immunity in the context of recommendations for measles PEP, review recent evidence on the effectiveness of Ig products and vaccines for measles PEP and provide updated guidance on options for measles PEP"--Guidance objective, page 5. |
| 650 | 0|aMeasles|xPrevention|xGovernment policy|zCanada. |
| 650 | 0|aMeasles|xVaccination|xGovernment policy|zCanada. |
| 650 | 0|aImmunoglobulins|xTherapeutic use|xGovernment policy|zCanada. |
| 650 | 0|aMeasles vaccine|xGovernment policy|zCanada. |
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
| 775 | 08|tRecommandations mises à jour sur la prophylaxie post-exposition contre la rougeole.|w(CaOODSP)9.947050 |
| 794 | |tUpdated recommendations on measles post-exposure prophylaxis.|b[June 2025 edition]|w(CaOODSP)9.951459 |
| 856 | 40|qPDF|s900 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-379-2025-eng.pdf|z(statement) |
| 856 | 40|qPDF|s334 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-379-2025-1-eng.pdf|z(summary) |